Skip to main content
Clinical Trials/NCT06249620
NCT06249620
Completed
Not Applicable

A Randomized Controlled Trial of Oral Suplementation With AM3, Hesperidin and Spermidine on Immunity Response and Biological Age in Healthy Volunteers.

Industrial Farmacéutica Cantabria, S.A.1 site in 1 country41 target enrollmentApril 19, 2022
ConditionsHealthy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
Industrial Farmacéutica Cantabria, S.A.
Enrollment
41
Locations
1
Primary Endpoint
Change in Biological Age
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The goal of this interventional study is to know the immune status of healthy participants and to obtain their biological age before and after two months of ingesting a dietary supplement. These individuals are compared with others who will be given a product of similar appearance, but without containing active components, being the constituents of the placebo group.

The study has a duration of 8 weeks, with 2 interventional visits (complete blood samples will be collected) at baseline and at 8 weeks.

In order to be included in the trial, the patient must read the Patient Information Sheet and sign the informed consent form.

The dosage regimen is two capsules per day in a single dose.

Detailed Description

Forty consenting volunteers will be included in this prospective, randomized, double-blind study and will be randomized by a statistician independent of the research team. The study consists of two milestones, in which different parameters are evaluated to finally reach the main goal, to measure their immune status and their biological age after taking the supplement (whose active ingredients include AM3, polyamines and flavonoids): - Complete blood samples are collected from participants at milestone 1. To determine immune functions; neutrophils, lymphocytes and NK cells are measured. The adherence and chemotaxis capacity of neutrophils and lymphocytes is determined, as well as neutrophil phagocytosis and lymphocyte proliferation. In addition, the release of pro-inflammatory and anti-inflammatory cytokines is assessed. In parallel, each participant will be given a survey to assess their perception of stress, which they will have to complete before and after 2 months of ingestion of the product (experimental and placebo). - In milestone 2, oxidative and inflammatory stress parameters are analyzed. Regarding oxidative stress: catalase activity, glutathione reductase activity and reduced glutathione concentration are measured. In terms of inflammatory stress: concentrations of both proinflammatory and anti-inflammatory cytokines released are measured.

Registry
clinicaltrials.gov
Start Date
April 19, 2022
End Date
October 1, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Industrial Farmacéutica Cantabria, S.A.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy volunteers who give their consent for the study will be included after having read and understood the information provided in the informed consent document
  • Between 29-65 years old
  • Residents in the Community of Madrid

Exclusion Criteria

  • Volunteers with no allergies or intolerances to the product
  • Patologies
  • Excessive alcohol consumption
  • Pregnant women
  • Antioxidants intake from supplements

Outcomes

Primary Outcomes

Change in Biological Age

Time Frame: Baseline and Week 8

The Biological Age will be determined at baseline and week 8, by using the mathematical model 'Immunity Clock', based on the the natural killer activity, Lymphoproliferation and phagocytosis, and neutrophils and lymphocyts chemotaxis

Secondary Outcomes

  • Change in Glutathione peroxidase levels(Baseline and week 8)
  • Change in Glutathione reductase levels(Baseline and week 8)
  • Change in cytotoxic activity of natural killer(Baseline and week 8)
  • Change in phagocytosis activity(Baseline and week 8)
  • Change in catalase activity with the use of a spectrophotometer(Baseline and week 8)
  • Change in inflammatory and anti-inflammatory cytokines levels(Baseline and week 8)
  • Change in Malondialdehyde concentrations(Baseline and week 8)
  • Change in neutrophil levels(Baseline and week 8)
  • Change in reduced/oxized glutathione concentrations (GSH/GSSG)(Baseline and week 8)
  • Change in lymphocyte levels(Baseline and week 8)
  • Change in lymphoproliferation levels(Baseline and week 8)
  • Change in chemotaxis index(Baseline and week 8)

Study Sites (1)

Loading locations...

Similar Trials